Published in J Endocrinol Invest on September 23, 2011
Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest (2013) 2.08
The rachitic tooth. Endocr Rev (2013) 0.96
Mechanisms of osteoclast-dependent bone formation. Bonekey Rep (2013) 0.94
Bone disease in primary hyperparathyrodism. Ther Adv Musculoskelet Dis (2012) 0.89
The role of the gastrointestinal tract in calcium homeostasis and bone remodeling. Osteoporos Int (2013) 0.85
Role of TGF-β in a mouse model of high turnover renal osteodystrophy. J Bone Miner Res (2014) 0.85
International Union of Basic and Clinical Pharmacology. XCIII. The parathyroid hormone receptors--family B G protein-coupled receptors. Pharmacol Rev (2015) 0.83
Developmental cues for bone formation from parathyroid hormone and parathyroid hormone-related protein in an ex vivo organotypic culture system of embryonic chick femora. Tissue Eng Part C Methods (2012) 0.82
Prolonged treatment with vitamin D in postmenopausal women with primary hyperparathyroidism. Endocr Connect (2012) 0.82
Renal Clearance of Mineral Metabolism Biomarkers. J Am Soc Nephrol (2015) 0.82
Connexins and pannexins in the skeleton: gap junctions, hemichannels and more. Cell Mol Life Sci (2015) 0.81
Comparison of treatment effects of teriparatide and the bisphosphonate risedronate in an aged, osteopenic, ovariectomized rat model under various clinical conditions. J Bone Miner Metab (2015) 0.80
MKP1-dependent PTH modulation of bone matrix mineralization in female mice is osteoblast maturation stage specific and involves P-ERK and P-p38 MAPKs. J Endocrinol (2013) 0.80
Redefining Human Vitamin D Sufficiency: Back to the Basics. Bone Res (2013) 0.78
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. J Endocrinol Invest (2016) 0.77
Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients. Osteoporos Int (2015) 0.77
Radon balneotherapy and physical activity for osteoporosis prevention: a randomized, placebo-controlled intervention study. Radiat Environ Biophys (2014) 0.76
Inherited disorders of calcium and phosphate metabolism. Curr Opin Pediatr (2014) 0.76
Genetic determinants of fibro-osseous lesions in aged inbred mice. Exp Mol Pathol (2015) 0.76
Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism. Endocrine (2016) 0.75
Long term effects on mineral and bone metabolism by low versus standard calcium dialysate in peritoneal dialysis: a meta-analysis. Int J Clin Exp Med (2015) 0.75
Calcium Supplementation Attenuates Disruptions in Calcium Homeostasis during Exercise. Med Sci Sports Exerc (2017) 0.75
Adult-Onset Deletion of β-Catenin in (10kb)Dmp1-Expressing Cells Prevents Intermittent PTH-Induced Bone Gain. Endocrinology (2016) 0.75
Mechanisms of Normalisation of Bone Metabolism during Recovery from Hyperthyroidism: Potential Role for Sclerostin and Parathyroid Hormone. Int J Endocrinol (2015) 0.75
Osteocytes and Skeletal Pathophysiology. Curr Mol Biol Rep (2015) 0.75
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med (2006) 7.45
Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell (2008) 5.93
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet (2001) 5.72
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem (2005) 5.33
Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med (1980) 4.96
A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med (1999) 4.91
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res (2008) 4.82
The study of hyperparathyroidism at the Massachusetts General Hospital. N Engl J Med (1966) 4.45
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res (2009) 4.40
SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem (2005) 4.13
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet (2002) 4.00
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J (2005) 3.61
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology (2005) 3.42
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone (2007) 3.41
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res (2011) 3.25
Skeletal disease in primary hyperparathyroidism. J Bone Miner Res (1989) 3.00
SOST is a target gene for PTH in bone. Bone (2005) 2.94
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res (2001) 2.65
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med (2007) 2.64
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res (2005) 2.61
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res (2003) 2.50
Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem (2003) 2.44
Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res (2003) 2.38
Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res (1999) 2.37
Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab (2000) 2.14
The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab (2008) 2.12
Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab (2010) 2.05
Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology (2001) 1.98
Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology (1999) 1.89
Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf) (2009) 1.87
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology (1997) 1.81
Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest (1997) 1.79
A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res (2005) 1.78
Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem (2002) 1.76
Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res (2007) 1.75
PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res (2011) 1.72
PTH and PTHrP signaling in osteoblasts. Cell Signal (2009) 1.69
PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res (2003) 1.61
Marked improvement in bone mass after parathyroidectomy in osteitis fibrosa cystica. J Clin Endocrinol Metab (1998) 1.58
Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med (2005) 1.58
Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology (1986) 1.52
The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab (1990) 1.51
Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem (2003) 1.48
Parathyroid hormone: past and present. J Endocrinol (2005) 1.46
Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone (2007) 1.43
Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res (2006) 1.41
The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. J Endocrinol (2006) 1.37
Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells. J Bone Miner Res (2007) 1.35
Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. J Biol Chem (2007) 1.34
IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone. J Bone Miner Res (2007) 1.32
Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol Metab (2010) 1.29
Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res (2003) 1.29
T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab (2008) 1.28
Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J Biol Chem (2002) 1.28
Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone. Bone (2005) 1.28
Parathyroid hormone bone anabolic action requires Cbfa1/Runx2-dependent signaling. Mol Endocrinol (2002) 1.26
Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice. Endocrinology (2005) 1.24
Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor signaling pathways to the anabolic effect of PTH on bone. Bone (2007) 1.24
Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J Bone Miner Res (1992) 1.23
PTH/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats. J Bone Miner Res (1995) 1.23
The effects of calcium regulating hormones on bone resorption by isolated human osteoclastoma cells. J Pathol (1985) 1.23
Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84. Bone (2008) 1.22
Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol (2010) 1.19
Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone (2006) 1.18
Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res (2001) 1.17
Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology (1993) 1.16
Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray. J Cell Biochem (2005) 1.15
Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab (2005) 1.14
Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab (1996) 1.13
Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. J Bone Miner Res (1995) 1.12
Parathyroid hormone uses multiple mechanisms to arrest the cell cycle progression of osteoblastic cells from G1 to S phase. J Biol Chem (2004) 1.12
Back pain and vertebral crush fractures: an unemphasized mode of presentation for primary hyperparathyroidism. Ann Intern Med (1975) 1.09
Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyperparathyroidism: A case-control study using HR-pQCT. J Bone Miner Res (2010) 1.08
Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent parathyroid hormone administration. Endocrinology (2008) 1.06
T cells: critical bone regulators in health and disease. Bone (2010) 1.04
Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS One (2010) 1.03
Parathyroid hormone and periosteal bone expansion. J Bone Miner Res (2002) 1.02
Risk of age-related fractures in patients with primary hyperparathyroidism. Arch Intern Med (1992) 1.00
The cell biology of parathyroid hormone in osteoblasts. Curr Osteoporos Rep (2008) 0.99
Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab (2009) 0.98
Bone strength in primary hyperparathyroidism. Osteoporos Int (2003) 0.96
Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblasts. J Cell Biochem (2005) 0.95
Parathyroid hormone suppresses osteoblast apoptosis by augmenting DNA repair. Bone (2009) 0.94
Effects of transient PTH on early proliferation, apoptosis, and subsequent differentiation of osteoblast in primary osteoblast cultures. Am J Physiol Endocrinol Metab (2006) 0.93
The risk of hip fractures in patients with primary hyperparathyroidism: a population-based cohort study with a follow-up of 19 years. J Intern Med (1993) 0.93
Role of PTH1R internalization in osteoblasts and bone mass using a phosphorylation-deficient knock-in mouse model. J Endocrinol (2010) 0.93
Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol. J Clin Invest (1993) 0.92
Microstructure of the trabecula and cortex of iliac bone in primary hyperparathyroidism patients determined using histomorphometry and node-strut analysis. J Bone Miner Metab (1999) 0.92
Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int (2000) 0.92
Parathyroid hormone as an anabolic skeletal therapy. Drugs (2005) 0.92
A comparative study of the bone-restorative efficacy of anabolic agents in aged ovariectomized rats. Osteoporos Int (2006) 0.92
Parathyroid hormone-responsive Smad3-related factor, Tmem119, promotes osteoblast differentiation and interacts with the bone morphogenetic protein-Runx2 pathway. J Biol Chem (2011) 0.91
Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med (1988) 0.90
Expression of p27Kip1 in osteoblast-like cells during differentiation with parathyroid hormone. Endocrinology (1997) 0.88
Distinct roles for mitogen-activated protein kinase phosphatase-1 (MKP-1) and ERK-MAPK in PTH1R signaling during osteoblast proliferation and differentiation. Cell Signal (2010) 0.86
Treatment of postmenopausal osteoporotic women with parathyroid hormone 1-84 for 18 months increases cancellous bone formation and improves cancellous architecture: a study of iliac crest biopsies using histomorphometry and micro computed tomography. J Musculoskelet Neuronal Interact (2005) 0.84
Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab (2001) 6.12
A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med (1999) 4.91
HIV disease and the endocrine system. N Engl J Med (1992) 3.48
Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int (2007) 3.12
Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab (1997) 3.00
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
Sex steroids and bone. Recent Prog Horm Res (2002) 2.17
Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab (2000) 2.14
Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab (1996) 1.92
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
Osteoporosis and low bone mass in premenopausal and perimenopausal women. Endocr Pract (2001) 1.81
Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab (1995) 1.79
Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int (2010) 1.74
Mechanism of tryptophanase induction in Escherichia coli. J Mol Biol (1967) 1.71
Neuromuscular disease in primary hyperparathyroidism. Ann Intern Med (1974) 1.69
Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int (2009) 1.63
Primary hyperparathyroidism: clinical and biochemical features. Medicine (Baltimore) (1974) 1.63
Marked improvement in bone mass after parathyroidectomy in osteitis fibrosa cystica. J Clin Endocrinol Metab (1998) 1.58
Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab (1998) 1.56
Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab (2007) 1.53
On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab (1999) 1.53
Assessment of trabecular and cortical architecture and mechanical competence of bone by high-resolution peripheral computed tomography: comparison with transiliac bone biopsy. Osteoporos Int (2009) 1.52
The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab (1990) 1.51
The influence of hyperthyroidism and hypothyroidism on alpha- and beta-adrenergic receptor systems and adrenergic responsiveness. Endocr Rev (1983) 1.51
Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab (1998) 1.49
Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone (2007) 1.43
The hypothalamus-pituitary-adrenal axis in HIV disease. AIDS Read (2003) 1.42
The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med (1999) 1.40
Primary hyperparathyroidism: still evolving? J Bone Miner Res (1997) 1.39
Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med (1990) 1.39
Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab (2007) 1.39
"Evidence-based" or "logic-based" medicine? Osteoporos Int (2010) 1.38
Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int (2011) 1.33
Effect of beta-adrenergic catecholamines on sodium transport in turkey erythrocytes. J Biol Chem (1973) 1.31
Parathyroid carcinoma: a review of 62 patients. Endocr Rev (1982) 1.30
Tumor necrosis factor and the p55TNF receptor are required for optimal development of the marginal sinus and for migration of follicular dendritic cell precursors into splenic follicles. Cell Immunol (2000) 1.25
Clinical review 63: Diabetes and pancreatic cancer: clues to the early diagnosis of pancreatic malignancy. J Clin Endocrinol Metab (1994) 1.25
Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J Bone Miner Res (1992) 1.23
Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2006) 1.21
Clinical review 123: Anabolic therapy for osteoporosis. J Clin Endocrinol Metab (2001) 1.21
Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab (2010) 1.21
Pseudogout after parathyroidectomy. Lancet (1973) 1.19
Fura-2 fluorescence is localized to mitochondria in endothelial cells. Am J Physiol (1987) 1.19
Enhanced platelet adherence and aggregation in Chagas' disease: a potential pathogenic mechanism for cardiomyopathy. Am J Trop Med Hyg (1990) 1.18
Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med (1997) 1.17
Subclassification of beta-adrenergic receptors in cultured rat cardiac myoblasts and fibroblasts. Circ Res (1980) 1.16
Bone densitometry: the best way to detect osteoporosis and to monitor therapy. J Clin Endocrinol Metab (1999) 1.16
A beta-adrenergic receptor of the turkey erythrocyte. I. Binding of catecholamine and relationship to adenylate cyclase activity. J Biol Chem (1973) 1.15
Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab (1996) 1.13
The anabolic effects of parathyroid hormone. Osteoporos Int (2002) 1.13
Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. J Bone Miner Res (1995) 1.12
Hypoxia-induced increased permeability of endothelial monolayers occurs through lowering of cellular cAMP levels. Am J Physiol (1992) 1.12
Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids (1999) 1.10
The influence of hypermagnesemia on serum calcium and parathyroid hormone levels in human subjects. N Engl J Med (1984) 1.10
Identification and persistence of beta adrenergic receptors during maturation of the rat reticulocyte. Mol Pharmacol (1977) 1.10
Preoperative localization of abnormal parathyroid tissue. Cumulative experience with venous sampling and arteriography. Am J Med (1973) 1.09
Parathyroid localization by angiographic techniques in patients with previous neck surgery. Br J Radiol (1973) 1.09
Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab (2012) 1.08
Pathophysiological insights into the cardiomyopathy of Chagas' disease. Circulation (1990) 1.06
Parathyroid carcinoma in familial hyperparathyroidism. Am J Med (1974) 1.05
A referent bone mineral density database for Chinese American women. Osteoporos Int (2006) 1.05
A beta-adrenergic receptor of the turkey erythrocyte. II. Characterization and solubilization of the receptor. J Biol Chem (1973) 1.05
The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Invest (2007) 1.04
Endothelial cells contain beta adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol (1984) 1.02
Acquisition by innervated cardiac myocytes of a pertussis toxin-specific regulatory protein linked to the alpha 1-receptor. Science (1985) 1.01
Perspective: nonreproductive sites of action of reproductive hormones. Endocrinology (2001) 1.01
TNF modulates endothelial properties by decreasing cAMP. Am J Physiol (1995) 1.00
Acute primary hyperparathyroidism. Am J Med (1987) 0.99
Tc99m-sestamibi uptake in osteitis fibrosa cystica simulating metastatic bone disease. J Clin Endocrinol Metab (2001) 0.99
Bacterial adherence to plastics: a role in endoscope-transmitted infections. Lancet (1984) 0.99
Alterations in intracellular calcium following infection of human endothelial cells with Trypanosoma cruzi. Mol Biochem Parasitol (1988) 0.99
Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry. Osteoporos Int (2008) 0.99
A radioreceptor assay for propranolol. Clin Pharmacol Ther (1979) 0.97
Hypocalcemic emergencies. Endocrinol Metab Clin North Am (1993) 0.97
Abnormalities in parathyroid hormone secretion and 1,25-dihydroxyvitamin D3 formation in women with osteoporosis. N Engl J Med (1989) 0.96
Bone mineral density in women with type II diabetes mellitus. J Bone Miner Res (1989) 0.96
Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am J Med (1989) 0.96
Therapeutic controversies in primary hyperparathyroidism. J Clin Endocrinol Metab (1999) 0.95
Reduced sensitivity of lymphocyte beta-adrenergic receptors in patients with endogenous depression and psychomotor agitation. N Engl J Med (1985) 0.94
The effects of nucleotides on the expression of beta-adrenergic adenylate cyclase activity in membranes from turkey erythrocytes. J Biol Chem (1974) 0.94
Effects of ouabain and isoproterenol on potassium influx in the turkey erythrocyte. Quantitative relation to ligand binding and cyclic AMP generation. Biochim Biophys Acta (1980) 0.94
Response of 1alpha,25-dihydroxyvitamin D3 to hypocalcemia in human subjects. N Engl J Med (1978) 0.93
Repeated neck exploration in primary hyperparathyroidism: localization of abnormal glands by selective thyroid arteriography, selective venous sampling, and radioimmunoassay. Surgery (1973) 0.93
The role of guanyl nucleotides in the expression on of catecholamine-responsive adenylate cyclase during maturation of the rat reticulocyte. Mol Pharmacol (1977) 0.93
The hemodynamic basis for the cardiac effects of parathyroid hormone (PTH) and PTH-related protein. Endocrinology (1995) 0.93
Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab (1992) 0.92
Organ transplantation and osteoporosis. Curr Opin Rheumatol (1995) 0.91
The medical management of primary hyperparathyroidism. Ann Intern Med (1982) 0.91
Hypoparathyroidism and elevated muscle enzymes. Neurology (1980) 0.91
Structure-binding-activity analysis of beta-adrenergic amines--I. Binding to the beta receptor and activation of adenylate cyclase. Biochem Pharmacol (1978) 0.91
Stimulation of inositol phosphate formation in ROS 17/2.8 cell membranes by guanine nucleotide, calcium, and parathyroid hormone. J Bone Miner Res (1989) 0.91
The influence of hyperthyroidism and hypothyroidism on the beta-adrenergic responsiveness of the turkey erythrocyte. J Clin Invest (1979) 0.91
A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve type 2 diabetes mellitus patients. Diabetes Obes Metab (2011) 0.90
Preoperative localization of hyperfunctioning parathyroid tissue: radioimmunoassay of parathyroid hormone in plasma from selectively catheterized thyroid veins. Ann Surg (1973) 0.90
Parathyroid hormone stimulates circulating osteogenic cells in hypoparathyroidism. J Clin Endocrinol Metab (2010) 0.90
Verapamil ameliorates clinical, pathologic and biochemical manifestations of experimental chagasic cardiomyopathy in mice. J Am Coll Cardiol (1989) 0.90
Bone disease in primary hyperparathyroidism. Endocrinol Metab Clin North Am (1990) 0.89
Correlation between 25-hydroxyvitamin D levels and latitude in Brazilian postmenopausal women: from the Arzoxifene Generations Trial. Osteoporos Int (2013) 0.89
Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel. J Clin Densitom (1999) 0.89